WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016187068) ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2016/187068 International Application No.: PCT/US2016/032547
Publication Date: 24.11.2016 International Filing Date: 13.05.2016
IPC:
C07K 16/28 (2006.01) ,A61K 38/19 (2006.01) ,A61P 35/02 (2006.01) ,A61P 35/04 (2006.01)
Applicants: THE GENERAL HOSPITAL CORPORATION[US/US]; 55 Fruit Street Boston, MA 02144, US
Inventors: FAUSTMAN, Denise L.; US
Agent: ARMSTRONG, Todd; US
Priority Data:
62/162,44915.05.2015US
62/276,07307.01.2016US
Title (EN) ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES
(FR) ANTICORPS ANTAGONISTES DE LA SUPERFAMILLE DU RÉCEPTEUR DU FACTEUR DE NÉCROSE ANTI-TUMORAL
Abstract: front page image
(EN) Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T- lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
(FR) L'invention concerne des polypeptides antagonistes de la superfamille du TNFR, tels que des anticorps et des fragments de liaison à l'antigène de ceux-ci, ainsi que l'utilisation de ces polypeptides pour inhiber la prolifération des lymphocytes T régulateurs (T-reg). Par exemple, des anticorps de l'invention comprennent des anticorps antagonistes de TNFR2 et des fragments de liaison à l'antigène de ceux-ci, et peuvent être utilisés pour supprimer la désactivation induite par T-reg des lymphocytes T réactifs à une tumeur, ainsi que pour traiter une grande diversité de cancers et de maladies infectieuses.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)